370 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
MDT Medtronic plc $96.03 $129.69B N/A
Article Searches
Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark http://www.zacks.com/stock/news/747407/medtronics-cobalt-crome-heart-devices-portfolio-gets-ce-mark?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-747407 Feb 03, 2020 - Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.
Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More http://www.zacks.com/stock/news/736676/medical-products-earnings-due-on-jan-29-algn-holx-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-736676 Jan 28, 2020 - A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
New Alliances Aid Quest Diagnostics Despite Reimbursement Woes http://www.zacks.com/stock/news/735308/new-alliances-aid-quest-diagnostics-despite-reimbursement-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-735308 Jan 27, 2020 - Quest Diagnostics (DGX) is currently concentrating on diagnostic information services arm and disciplined capital deployment.
New Product Suite Boosts Intersect ENT Despite Cost Concerns http://www.zacks.com/stock/news/730542/new-product-suite-boosts-intersect-ent-despite-cost-concerns?cid=CS-ZC-FT-analyst_blog|zer_report_update-730542 Jan 23, 2020 - With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.
Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block http://www.zacks.com/stock/news/729175/medtronic-mdt-gets-fda-nod-for-micra-av-to-treat-av-block?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-729175 Jan 22, 2020 - Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.
Hill-Rom (HRC) Gains Ground on Global Expansion, New Menu http://www.zacks.com/stock/news/728036/hill-rom-hrc-gains-ground-on-global-expansion-new-menu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-728036 Jan 21, 2020 - Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.
Cardiovascular Systems (CSII) Stock Hits New 52-Week High http://www.zacks.com/stock/news/726525/cardiovascular-systems-csii-stock-hits-new-52-week-high?cid=CS-ZC-FT-analyst_blog|52-week_high/low-726525 Jan 20, 2020 - Cardiovascular Systems (CSII) is optimistic about maintaining its growth momentum on several recent developments.
Medtronic (MDT) Hits 52-Week High, Can the Run Continue? http://www.zacks.com/stock/news/726453/medtronic-mdt-hits-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-726453 Jan 20, 2020 - Medtronic (MDT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Boston Scientific Gets a Boost From New Products, Buyouts http://www.zacks.com/stock/news/722351/boston-scientific-gets-a-boost-from-new-products-buyouts?cid=CS-ZC-FT-analyst_blog|zer_report_update-722351 Jan 17, 2020 - Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.
3 Medical Product Stocks Set to Beat This Earnings Season http://www.zacks.com/stock/news/720638/3-medical-product-stocks-set-to-beat-this-earnings-season?cid=CS-ZC-FT-earnings_esp-720638 Jan 16, 2020 - Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Pages: 1234567...37

<Page 2>